Ikibazo gihuza ibibazo · Hagati Urwego

AI mu bigeragezo bya Clinical

Ongera usuzume uburyo AI ishyigikira guhuza abarwayi, igishushanyo mbonera, ubushakashatsi bujyanye n'imihindagurikire y'ikirere, kugenzura umutekano, no kwemeza amabwiriza mu bushakashatsi ku mavuriro.

Inzira zijyanye no kuyoboraAI Mubigeragezo bya Clinical
Ikibazo 1 Bya 8

Ni ikihe kibazo kimaze igihe kinini mubigeragezo bivura AI yibanda cyane?

Reba buri kibazo8 ibibazo

Ibisubizo nibisobanuro bigaragara mugihe ufata ikibazo.

  1. Ni ikihe kibazo kimaze igihe kinini mubigeragezo bivura AI yibanda cyane?
    • Buhoro kandi bigoye kwinjiza abarwayi
    • Ibara ryimiti ipakira
    • Ibitaro bya cafeteria
    • Parikingi iboneka ahabigenewe
  2. How can natural-language processing help screen patients for clinical trials?
    • Mugusiba isubiramo ryumutekano
    • Extract clinical information from electronic health records and compare it with trial eligibility criteria
    • Mu kwishyura abarwayi kuruta abanywanyi
    • Mugabanya urubanza kugeza kumunsi umwe
  3. What is an external control arm in a clinical trial?
    • Igikoresho cya robo
    • Molekile ikomoka kuri mudasobwa
    • A comparison group drawn from data outside the trial, such as historical or concurrent external data
    • Ububiko bwibitse bwa seriveri
  4. What can propensity-score matching do when constructing an external-control comparison?
    • Gutondeka inyuguti
    • Igisekuru gisanzwe cyonyine
    • Kugenzura
    • Balance measured baseline covariates related to treatment assignment
  5. Ni ukubera iki guhanura guta ishuri hamwe nibikorwa-byerekana imikorere bifite akamaro kubaterankunga?
    • Baretse abaterankunga kugira icyo bakora mbere yo guhagarara
    • Bashushanya inyubako
    • Bandika amagambo yo kwamamaza
    • Bahitamo imyenda y'abakozi
  6. What does FDA’s January 2025 draft AI guidance address for drugs and biologics?
    • Kugabanya ubushakashatsi bwose burundu
    • AI used to generate information supporting regulatory decisions about safety, effectiveness, or quality
    • Kuberako AI itemewe mubuvuzi
    • Kugabanya umubare wabaganga
  7. What can a Bayesian adaptive clinical-trial design change as evidence accumulates?
    • The original trial question after results are known
    • The identity of past participants
    • Trial elements such as dosing or allocation to study arms under prespecified rules
    • The inclusion criteria without documentation
  8. Which pharmacovigilance tasks does FDA identify as possible uses for emerging AI?
    • Only advertising click-through rates
    • Satellite images of clinical sites
    • Unrelated social-media sentiment about packaging
    • Adverse-event intake, data entry, processing, and safety-signal detection or evaluation